CA2010274C - Biodegradable surgical implants and devices - Google Patents
Biodegradable surgical implants and devices Download PDFInfo
- Publication number
- CA2010274C CA2010274C CA002010274A CA2010274A CA2010274C CA 2010274 C CA2010274 C CA 2010274C CA 002010274 A CA002010274 A CA 002010274A CA 2010274 A CA2010274 A CA 2010274A CA 2010274 C CA2010274 C CA 2010274C
- Authority
- CA
- Canada
- Prior art keywords
- implant
- set forth
- partially
- biodegradable
- fibres
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000007943 implant Substances 0.000 title claims abstract description 52
- 239000000463 material Substances 0.000 claims abstract description 26
- 230000002787 reinforcement Effects 0.000 claims abstract description 24
- 238000004804 winding Methods 0.000 claims abstract description 24
- 238000005304 joining Methods 0.000 claims abstract description 4
- 229920000642 polymer Polymers 0.000 claims description 38
- 210000001519 tissue Anatomy 0.000 claims description 36
- 229920001577 copolymer Polymers 0.000 claims description 22
- 239000011159 matrix material Substances 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 20
- 210000001724 microfibril Anatomy 0.000 claims description 15
- 229920002988 biodegradable polymer Polymers 0.000 claims description 12
- 239000004621 biodegradable polymer Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 9
- 210000000056 organ Anatomy 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000000919 ceramic Substances 0.000 claims description 5
- 210000004204 blood vessel Anatomy 0.000 claims description 4
- 230000003872 anastomosis Effects 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 239000004744 fabric Substances 0.000 claims description 3
- 238000009940 knitting Methods 0.000 claims description 3
- 238000010276 construction Methods 0.000 claims 1
- 229920000954 Polyglycolide Polymers 0.000 description 28
- 239000004633 polyglycolic acid Substances 0.000 description 27
- 229920001432 poly(L-lactide) Polymers 0.000 description 16
- 206010061592 cardiac fibrillation Diseases 0.000 description 13
- 230000002600 fibrillogenic effect Effects 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 11
- 210000003708 urethra Anatomy 0.000 description 11
- 206010052428 Wound Diseases 0.000 description 10
- 208000027418 Wounds and injury Diseases 0.000 description 10
- 239000013078 crystal Substances 0.000 description 10
- 229920000747 poly(lactic acid) Polymers 0.000 description 8
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 7
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 210000003462 vein Anatomy 0.000 description 7
- 210000000013 bile duct Anatomy 0.000 description 6
- 230000003014 reinforcing effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 238000001746 injection moulding Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920002635 polyurethane Polymers 0.000 description 4
- 239000004814 polyurethane Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 210000003932 urinary bladder Anatomy 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 229920001651 Cyanoacrylate Polymers 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- 238000001949 anaesthesia Methods 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000002861 polymer material Substances 0.000 description 3
- 229920006324 polyoxymethylene Polymers 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 229920001169 thermoplastic Polymers 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 2
- 229930182556 Polyacetal Natural products 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 238000005452 bending Methods 0.000 description 2
- 239000012867 bioactive agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002729 catgut Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000000748 compression moulding Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 210000003191 femoral vein Anatomy 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 239000004416 thermosoftening plastic Substances 0.000 description 2
- 210000000626 ureter Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229920002201 Oxidized cellulose Polymers 0.000 description 1
- 229920005689 PLLA-PGA Polymers 0.000 description 1
- 241001474977 Palla Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229920006125 amorphous polymer Polymers 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- 238000009954 braiding Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229910010293 ceramic material Inorganic materials 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000010218 electron microscopic analysis Methods 0.000 description 1
- 229950010048 enbucrilate Drugs 0.000 description 1
- JJJFUHOGVZWXNQ-UHFFFAOYSA-N enbucrilate Chemical compound CCCCOC(=O)C(=C)C#N JJJFUHOGVZWXNQ-UHFFFAOYSA-N 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000000886 hydrostatic extrusion Methods 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940107304 oxidized cellulose Drugs 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920006149 polyester-amide block copolymer Polymers 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011265 semifinished product Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
Abstract
(57) Abstract The invention relates to a surgical implant, a device or a part thereof made of a material which is at least partially biodegradable. It is intended for supporting and/or joining and/or separating tissues and/or operated and/or damaged tissues or parts thereof and/or for keeping open a tissue cavity. The implant, device or a part thereof consists at least partially of at least one, at least partially biodegradable elongated piece which is at least partially wound at least once around a winding centre into a helical configuration. The implant is at least partially reinforced with biodegradable reinforcement elements.
Fig. 10a
Fig. 10a
Description
Biodegradable surgical implants and devices The present invention relates to a surgical implant and/or device.
In surgery, it is prior known to employ at least partially biodegradable, elongated (typically tubular) surgical implants for .supporting, connecting or separating elongated organs, tissues or parts thereof, such as canals, ducts, tubes, intestines, blodd vessels, nerves etc. In this context, the biodegrad-able (absorbable, resorbable) material refers to a material whose decomposition and/or dissolution products leave the system through metabolic ducts, kidneys, lungs, intestines and/or skin by secretion.
US Patent No. 3 108 357, Liebig, discloses a tubular device to be implanted in animals and humans, compri-sing a resilient woven tube which contains biologically absorbable oxidized cellulose.
US Patent No. 3 155 095, Brown, discloses hollow cylindrical anastomosis joints which are made of an absorbable material.
US Patent No. 3 272 204, Artandi and Bechtol, discloses collagen-made flexible tubes which can be externally reinforced with a plastic coil or plastic rings.
US Patent No. 3 463 158, Schmitt and Polistina, discloses fibre-made tubular surgical devices which are at least partially made of absorbable polyglycolic acid (PGA).
US Patent No. 3 620 218, Schmitt and Polistina, discloses PGA-made surgical devices, such as tubes.
In surgery, it is prior known to employ at least partially biodegradable, elongated (typically tubular) surgical implants for .supporting, connecting or separating elongated organs, tissues or parts thereof, such as canals, ducts, tubes, intestines, blodd vessels, nerves etc. In this context, the biodegrad-able (absorbable, resorbable) material refers to a material whose decomposition and/or dissolution products leave the system through metabolic ducts, kidneys, lungs, intestines and/or skin by secretion.
US Patent No. 3 108 357, Liebig, discloses a tubular device to be implanted in animals and humans, compri-sing a resilient woven tube which contains biologically absorbable oxidized cellulose.
US Patent No. 3 155 095, Brown, discloses hollow cylindrical anastomosis joints which are made of an absorbable material.
US Patent No. 3 272 204, Artandi and Bechtol, discloses collagen-made flexible tubes which can be externally reinforced with a plastic coil or plastic rings.
US Patent No. 3 463 158, Schmitt and Polistina, discloses fibre-made tubular surgical devices which are at least partially made of absorbable polyglycolic acid (PGA).
US Patent No. 3 620 218, Schmitt and Polistina, discloses PGA-made surgical devices, such as tubes.
WO 84/03035, Barrows, discloses longitudinally open-able, porous, coarse-surfaced biodegradable tubes used as a remedy for the nerves.
The publication Plast. Rec. Surg. 74 (1984) 329, Daniel and Olding, discloses an absorbable anastomosis device which comprises cylindrical, tubular, complementary parts.
However, the prior known tubular, at least partially biodegradable surgical implants and devices involve several drawbacks and limitations. As for the implants including biostable parts, such as polymeric and like fibres, plastic or metallic coils or rings or the like, such biostable parts or components remain in the system even after a tissue or an organ has healed and such components can be later harmful to a patient by causing infections, inflammatory reactions and Tike foreign matter reactions and/or they might release particles, corrosion products or the like which aan wander in the system and/or cause harmful cellular level reactions.
The prior known 'tubular biodegradable implants manu-factured by melt working technique or a like method are often massive and stiff creating in resilient tissues (such as ducts, tubes, blood vessels etc.) an undesirable stiff, non-physiological bracing effect which can lead to harmful alterations in the properties of a tissue to be braced. In addition, the massive, tubular implants create a heavy local foreign matter loading on the system at the installation site thereof and such loading can also contribute to harmful alterations in an operated tissue, such as canal, tube, duct, blood vessel or the like.
On the other hand, the tubular structures constructed from biodegradable fibres by braiding, knitting, weaving or same other similar technique do not possess the structural rigidity and/or resilience often required of a support implant to be fitted inside or outside a tubular tissue.
It has been surprisingly discovered in this invention that the deficiencies and drawbacks of the prior known, at least partially biodegradable surgical implants and devices used for supporting, connecting or separating organs, tissues or parts thereof can be substantially eliminated with an implant, device or a part thereof which is mainly characterized by comprising an at least partially biodegradable elongated member which is at least partially wound at least once around a centre of rotation into a helical configuration and which is at least partially reinforced with biodegradable reinforcing elements.
According to one aspect of the present invention there is provided a surgical implant, device, or a part thereof made of a biodegradable material, which has been composed of a biodegradable matrix with biodegradable reinforcement elements therein, the said implant being at least partially wound at least once around a winding centre into a helical configuration, characterized in that the implant or device for separating tubular tissues and/or keeping open a tissue cavity in operated and/or damaged tissues is formed of one single rod.
An implant, device or a part thereof (hereinbelow "device") can be conceived having been formed in a manner that around a certain centre point is wound some elongated member at a distance of a certain winding radius from the centre point. If the winding centre is stationary and the winding radius increases as the winding angle increases, the configuration of an obtained device is a spiral configuration, especially if the winding radius remains in the same plane. Provided that the winding radius is constant and the winding centre travels during the turning of an elongated member along a certain, e.g.
linear path, the device obtained has a circle-cylindrical screw-threaded configuration (helix). On the other hand, if the winding radius changes while the winding centre travels along a certain path, there will be produced a spiral configuration whose external surface is in conical shape. It is obvious that the implant, device or a part thereof can include the above shapes and configurations as a combination and e.g. a combination of a spiral and a cylindrical screw-threaded configuration. The implant, device or a part thereof can also be provided with otherwise shaped members in addition to a screw-threaded configuration, such as plates, sleeves etc.
The invention relates also to a method for manufacturing an implant, device or a part thereof ("device"), as defined above, the method being characterized in that an elongated blank formed by a biodegradable polymer matrix and biodegradable reinforcement elements is wound at least partially at least once around a winding centre into a helical configuration.
The invention relates also to the use of an implant, device and a part thereof.
The invention is described in more detail in the following specification with reference made to the accompanying drawings. In the drawings fig. 1 shows the formation of a material micro-structure in a device of the invention in a perspective view schematically, an array of lamellae turning into a fibrillated structure, fig. 2 shows an intra- and inter-fibrillary molecular structure, fig. 3 shows schematically the micro-structure of a fibrillated polymer, fig. 4 shows schematically the molecular structure of fibrillated devices of the invention, ~~~.~~'~~ø
figs. 5 and 6 are schematical perspective views of spiral-shaped embodiments of the device, figs. 7a, b - ga, are schematical perspective views b of conical embodiments of the device, figs. l0a and lOb are schematic perspective views of a cylindrical embodiment of the device, figs. lOc and lOd show some further embodiments of a cylindrical device, figs. lla - 111 illustrate some preferred cross-sectional shapes and surface patterns for the elongated member (blank) of devices shown in figs. 5-10, figs. 12 and 13 illustrate one special embodiment of the invention schematically in a perspective view, fig. 14 shows schematically a test arrangement described in example fig. 15 illustrates a surgical operation described in example 3, fig. l6 illustrates a surgical operation described in example 4, fig. 17 shows schematically an device described in example 5, and fig. 18 shows one embodiment for an device of the invention.
In this context, the biodegradable reinforcing elements refer to the following:
(a) orientated (aligned) structural units included in the micro-structure (molecular structure) of a material, such as orien-tated parts of molecu:Les, bundles of molecules or parts thereof or microfibrils, fibrils or the like orientated structural units formed thereby, (b) biodegradable organic filaments, fibres, membrane fibres or the like or structures constructed thereof, such as bands, braids, yarns, fabrics, non-woven structures or the like; or (c) biodegradable inorganic (ceramic) file-ments, fibres, membrane fibres or the like or structures constructed thereof:
A particularly preferred embodiment of the invention is such an implant or an device which is structurally self-reinforced. A self--reinforced biodegradable structure is defined in the invention US Patent No. 4 743 257, Tormala, et al. In a self-reinforced struc-ture, a biodegradable polymer matrix is reinforced with biodegradable reinforcement elements (units) having the same proportional elemental composition as the matrix. The reinforcement elements are typically ori~emta.~ed moleculesv or parts thereof or the like obtained by orientation or fibrils, microfibrils, fibres, filaments or the like structures constructed thereof.
Reinforcement elements inside the microstructure of a self-reinforced polymer material are produced e.g. by orientating the molecular structure of a material either in melt state or in solid state in such condi-tions the structure-reinforcing orientation remains at least partially permanently in material either as a result of the rapid cooling and/or solid state of the melt and/or as a result of the prevention of molecular movements (relaxation) of the melt. The self-reinforcement based on draw orientation is described in the invention CVO 88/05312, Tormala et al., as follows:
A partially crystalline, non-oriented piece of polymer typically consists of crystal units i.e. spherulites and amorphous areas thereinside and/or therebetween.
The orientation and fibrillation of a polymer system possessing a spherulitic crystalline structure is a process that has been extensively studied in connection with the production of thermoplastic fibres. For example, the invention US Patent 3 161 709 discloses a three-step drawing process for.transforming a melt-worked polypropene filament into a fibre having a high tensile strength.
The mechanism of orientation and fibrillation is basically as follows (C. L. Choy et al. Polym. Eng.
Sci. 23, 1983, p. 910). As a partially crystalline polymer is being drawn, the molecule chains of crystal lamellae quickly begin to parallel themselves (orien-tate) in the drawing direction. Simultaneously the spherulites extend in length and finally break.
Crystal blocks detach from lamellae and join together as queues by means of tight tie-molecules which are formed through the partial release of polymer chains from crystal lamellae. The alternating amorphous and s ~~1. t~~, ~~, crystalline zones, together with tight tie-molecules, form long, thin (appr. 100 ~ wide) microfibrils which are paralleled in the drawing direction. Since the intrafibrillar tie-molecules form in the phase boun-daries between crystal blocks, they will be mainly located on the external surface of microfibrils.
Those tie-molecules, which link various lamellae in an isotropic material prior to drawing, serve in a fibrillated material to link various microfibrils together i.e. become interfibrillar tie-molecules which are located in boundary layers between'adjacent microfibrils.
Fig. 1 illustrates schematically the transformation of an array of lamellae into a fibrillar structure (a fibril consisting of a bunch of microfibrils) due to the action of water and fig. 2 shows some of the molecular structure inside and between miarofibrils.
Fig. 3 illustrates schematically some of the structure of a fibrillated polymer. The figure shows several fibrils (one being dyed grey for the sake of clarity) which consist of a plurality of micro.fibrils having a length, of several microns.
Orientation is initiated right at the start of drawing and also a fibrillated structure is formed at rather low drawing ratios x (wherein ~ - length of piece after drawing/length of piece prior to drawing). For example, HD-polyethene is clearly fibrillated at a value 8 and polyacetal (POM) at a value 3.
As the drawing of a fibrillated structure is continued further (this stage of the process is often referred to as ultra-orientation), the structure is further deformed with microfibrils sliding relative to each other to further increase the proportional volume of straightened interfibrillar tie-molecules. If drawing is effected at a sufficiently high temperature, the oriented tie-molecules crystallize and build axial crystalline bridges which link together crystalline blocks.
The excellent strength and modulus of elasticity properties of a fibrillated structure are based on the vigorous orientation of polymer molecules and polymer segments in the direction of drawing (in the direction of the longitudinal axis of microfibrils) characteris tic of the structure.
The fibrillation of macroscopic polymeric blanks, such as rods or tubes, is prior known in the cases of biostable polyacetal and polyethene (see e.g. K.
Nakagawa and T. iConaka, Polymer 27, 19$6, p. 1553 and references included therein). 'What has not been prior known, however, is the orientation and fibril lation of at least partially helical and/or spiral or similarly shaped members or pieces manufactured from biodegradable polymers.
The at least partial orientation and/or fibrillation of a biodegradable helical and/or spiral or similar piece can be effected e.g. by rapidly chilling a flowing state (e.g. in an injection mould) polymer w melt into a solid state in a manner that the orienta-tion of molecules existing in the flowing melt in flowing direction is not allowed to discharge through molecular movements either entirely or partially inta a state of random orientation.
A more vigorous orientation and fibrillation and thus also improved mechanica l qualities are generally provided for a polymer piece by mechanically working the material (orientation), generally drawing or hydrostatic extrusion or die-drawing in such a physical condition (usually in solid state), wherein it is possible for the material to undergo dramatic struc-tural deformations in its crystalline structures and amorphous areas occurring at molecular level for creating orientation and fibrillation. As a result of fibrillation, e.g. a resorbable polymer material produced by injection moulding or extrusion and initially possessing mainly a spherolitic crystalline structure transforms into a fibrillated structure which.
is vigorously oriented in the direction of drawing and comprises e.g, elongated crystalline microfibrils as well as tie-molecules linking them as well as oriented amorphous areas. In a partially fibrillated structure, the amorphous areas between microfibrils make up a more substantial portion. of the material than in an ultra-oriented material which, in the most preferred case, only includes amorphousness as crystal defects. As a result of orientation, fibrillation and ultra-orien tation the values of strength and modulus of elasticity of a material are multiplied compared to a non-fibril lated structure.
Orientation and the resulting fibrillation can be used for treating biodegradable polymers, copalymers and polymer compositions so as to farm self-reinforced composites in which nearly the entire material stock is oriented in a desired fashion and the portion of amorphous matrix is small, these being the reasons why such materials have extremely high quality strength properties in orientation direction: bending strength e.g. up to 400-1500 MPa and modulus of elasticity 20-50 GPa and thus the orientation and fibrillation can be used to provide helixes or spirals or the like devices with multiple strength values compared to those of normal melt-processed biodegradable materials, which are typically in the order of 30-80 MPa.
The same way as in the fibrillated structure of polymer fibres, also in the structure of fibrillated devices there can be found e.g. the following structural units which are schematically shown in fig. 4: crystalline blocks, the stock therebetween comprising an amorphous material (e.g. loose polymer chains, chain ends and molecular folds), tie-molecules which link the crystal-line blocks together (the number and tightness of these increases as drawing ratio a increases) as well as possible crystalline bridges between crystal-line blocks. Bridges can form during the drawing as tie-molecules orientate and group themselves as bridges (C. L. Choy et al. J. Polym. Sci., Polym. Phys. Ed., 19, 1981, p. 335).
The oriented fibrillated structure shown in figs. 1-4 is already developed by using so-called "natural"
drawing ratios 3-8. As drawing is then continued as ultra-orientation, the portion of crystalline bridges can increase to be quite considerable whereby, in the extreme case, the bridges and crystal blocks provide a continuous crystalline structure. However, the effects of tie-molecules and bridges are often similar and, thus, the exact distinction thereof from each other is not always possible.
Orientation and fibrillation can be experimentally characterized by the application of several different methods. Orientation function fc, which can be determined by X-ray diffraction measurements, charac-terizes orientation of the molecule chains of a crystalline phase. Generally, fc already reaches a maximum value of 1 by natural drawing ratios (a < 6).
For polymer materials having a spherolitic structure fc » 1.
Double-refraction ( ~;,) measured with a polarization microscope is also a quantity which represents the orientation of molecule chains. It generally increases at natural drawing ratios ( a < 6) vigorously and lz thereafter in ultra-orientation more slowly, which indicates that the molecule chains of a crystalline phase orientate vigorously in the drawing direction at natural drawing ratios and orientation of the molecules of an amorphous phase continues further at higher drawing ratios (C.L. Choy et al. Polym Eng. Sci., 23, 1983, p. 910).
The formation of a fibrillous structure can also be demonstrated visually by studying the fibrillated material by means of optical and/or electronic micros-copy (see e.g. T. Konaka et al. Polymer, 26, 1985, p.
462). Even the individual fibrils consisting of microfibrils can be clearly distinguished in scanning electron microscope images of a fibrillated structure.
An oriented and/or fibrillated and/or ultra-oriented piece (blank) is then rotated at least once around a centre of rotation into a helical configuration to form 20, "an device" of the invention by shaping it at least partially by means of an external force or pressure and/or external heat and/or by means of heat induceable in the piece (e.g. by radiowave radiation). In practice, the rotation of winding of the device is effected in a manner that an elongated blank is wound around a suitable, if necessary heated mould (e.g. a mould of cylindrical shape). Such a mould is typically round in cross-sectionso as to produce helical shapes having a circular cross-section. The cross-sectianal shape of a mould can also be elliptical, oval, angular etc, to produce helical shapes having various cross-sections. Orientation, fibrillation or ultra-orien-tation can also be effected in a continuous action and/or simultaneously with winding in a manner that an elongated blank is being drawn arid the drawn section is simultaneously wound around a cylindrical mould.
At least partially oriented and/or fibrillated and particularly yltra-oriented biodegradable devices are an example of an oriented, self-reinforced biodegrad-able (US Patent 4 743 257, T~irmala et al.) composite material, wherein the oriented reinforcement elements (such as fibrils, microfibrils, crystal blocks, tie-molecules or crystallized bridges) are formed and/or grouped during a mechanical working and a phase binding those elements consists e.g. of the following struc-tural elements: amorphous phase, interfaces between crystal blocks as well as interfaces between bridges and microfibrils, a typical feature of which is also a vigorous orientation in drawing direction.
Another method for using biodegradable reinforcement elements in devices of the invention is the reinforce-ment thereof with fibres manufactured from polymer, copolymer or a polymer composition, with film fibres, filaments or structures constructed threof, such as braids, threads, ribbons, non-woven structures, fabrics, knittings or the li:ke, by combining ready-made fibres with a suitable polydmer matrix. Such fibres can be manufactured E~.g. from biodegradable polymers set forth in table :l. The fibres can also be biodegradable ceramic fibres, such as calcium phosphate fibres (see e.g. S. Vainionpaa et al., Progr. Polym. Sci. , Progr. Polym. Sci., 14 (1989) 679-716.
Various plastic technological methods can be applied to manufacture devices of the invention reinforced with biodegradable organic and/or inorganic fibres or with structures constructed threof, said manufacturing being carried out by binding the reinforcement structures at least partially to each other with biodegradable polymer, copolymer or a polymer composition (matrix) in such conditions which serve to produce a sufficient-ly equal quality composite from the matrix and rein-forcement elements, said matrix being usually in solution or melt state. Methods for combining rein-forcement fibres or the like and a matrix as well as for processing them into semi-finished products and/or devices include e.g. injection moulding, extrusion, pultrusion, winding, compression moulding etc.
The at least partially spirally shaped, at least partially biodegradable device of the invention can be used in a versatile manner for supporting, expand-ing, joining or separating organs, tissues or parts threof. An device of the invention offers a plurality of benefits over the prior art implants and devices or devices. When using an device of the invention, the amount of foreign matter remains smaller than with traditional implant tubes. Devices of the invention are more flexible and resilient than the rigid prior art tubes and, on the other hand, devices of the invention are stronger under compression and retain their shape better than fibre-constructed tubular devices, whereby devices of the invention are capable of being used for retaining open or even expanding the medullary cavity of tubular tissues.
Devices of the invention can be manufactured from biodegradable polymers, copolymers and polymer compo-sitions. Table 1 shows a number of prior known biodegradable palymers, which or mixtures of which can be used as raw materials for devices of the invention both as a matrix (or binder polymers) and/or reinfor cement elements.
~'~~.~~
Table 1. Biodegradable polymers 1. Polyglycolide (PGA) Copolymers of alycolide 10 2. Glycolide/lactide copolymers (PGA/PLA) 3. Glycolide/trimethylene carbonate copolymers (PGA/TMC) Polylactides (PLA) Stereoisomers and copolymers of PLA
The publication Plast. Rec. Surg. 74 (1984) 329, Daniel and Olding, discloses an absorbable anastomosis device which comprises cylindrical, tubular, complementary parts.
However, the prior known tubular, at least partially biodegradable surgical implants and devices involve several drawbacks and limitations. As for the implants including biostable parts, such as polymeric and like fibres, plastic or metallic coils or rings or the like, such biostable parts or components remain in the system even after a tissue or an organ has healed and such components can be later harmful to a patient by causing infections, inflammatory reactions and Tike foreign matter reactions and/or they might release particles, corrosion products or the like which aan wander in the system and/or cause harmful cellular level reactions.
The prior known 'tubular biodegradable implants manu-factured by melt working technique or a like method are often massive and stiff creating in resilient tissues (such as ducts, tubes, blood vessels etc.) an undesirable stiff, non-physiological bracing effect which can lead to harmful alterations in the properties of a tissue to be braced. In addition, the massive, tubular implants create a heavy local foreign matter loading on the system at the installation site thereof and such loading can also contribute to harmful alterations in an operated tissue, such as canal, tube, duct, blood vessel or the like.
On the other hand, the tubular structures constructed from biodegradable fibres by braiding, knitting, weaving or same other similar technique do not possess the structural rigidity and/or resilience often required of a support implant to be fitted inside or outside a tubular tissue.
It has been surprisingly discovered in this invention that the deficiencies and drawbacks of the prior known, at least partially biodegradable surgical implants and devices used for supporting, connecting or separating organs, tissues or parts thereof can be substantially eliminated with an implant, device or a part thereof which is mainly characterized by comprising an at least partially biodegradable elongated member which is at least partially wound at least once around a centre of rotation into a helical configuration and which is at least partially reinforced with biodegradable reinforcing elements.
According to one aspect of the present invention there is provided a surgical implant, device, or a part thereof made of a biodegradable material, which has been composed of a biodegradable matrix with biodegradable reinforcement elements therein, the said implant being at least partially wound at least once around a winding centre into a helical configuration, characterized in that the implant or device for separating tubular tissues and/or keeping open a tissue cavity in operated and/or damaged tissues is formed of one single rod.
An implant, device or a part thereof (hereinbelow "device") can be conceived having been formed in a manner that around a certain centre point is wound some elongated member at a distance of a certain winding radius from the centre point. If the winding centre is stationary and the winding radius increases as the winding angle increases, the configuration of an obtained device is a spiral configuration, especially if the winding radius remains in the same plane. Provided that the winding radius is constant and the winding centre travels during the turning of an elongated member along a certain, e.g.
linear path, the device obtained has a circle-cylindrical screw-threaded configuration (helix). On the other hand, if the winding radius changes while the winding centre travels along a certain path, there will be produced a spiral configuration whose external surface is in conical shape. It is obvious that the implant, device or a part thereof can include the above shapes and configurations as a combination and e.g. a combination of a spiral and a cylindrical screw-threaded configuration. The implant, device or a part thereof can also be provided with otherwise shaped members in addition to a screw-threaded configuration, such as plates, sleeves etc.
The invention relates also to a method for manufacturing an implant, device or a part thereof ("device"), as defined above, the method being characterized in that an elongated blank formed by a biodegradable polymer matrix and biodegradable reinforcement elements is wound at least partially at least once around a winding centre into a helical configuration.
The invention relates also to the use of an implant, device and a part thereof.
The invention is described in more detail in the following specification with reference made to the accompanying drawings. In the drawings fig. 1 shows the formation of a material micro-structure in a device of the invention in a perspective view schematically, an array of lamellae turning into a fibrillated structure, fig. 2 shows an intra- and inter-fibrillary molecular structure, fig. 3 shows schematically the micro-structure of a fibrillated polymer, fig. 4 shows schematically the molecular structure of fibrillated devices of the invention, ~~~.~~'~~ø
figs. 5 and 6 are schematical perspective views of spiral-shaped embodiments of the device, figs. 7a, b - ga, are schematical perspective views b of conical embodiments of the device, figs. l0a and lOb are schematic perspective views of a cylindrical embodiment of the device, figs. lOc and lOd show some further embodiments of a cylindrical device, figs. lla - 111 illustrate some preferred cross-sectional shapes and surface patterns for the elongated member (blank) of devices shown in figs. 5-10, figs. 12 and 13 illustrate one special embodiment of the invention schematically in a perspective view, fig. 14 shows schematically a test arrangement described in example fig. 15 illustrates a surgical operation described in example 3, fig. l6 illustrates a surgical operation described in example 4, fig. 17 shows schematically an device described in example 5, and fig. 18 shows one embodiment for an device of the invention.
In this context, the biodegradable reinforcing elements refer to the following:
(a) orientated (aligned) structural units included in the micro-structure (molecular structure) of a material, such as orien-tated parts of molecu:Les, bundles of molecules or parts thereof or microfibrils, fibrils or the like orientated structural units formed thereby, (b) biodegradable organic filaments, fibres, membrane fibres or the like or structures constructed thereof, such as bands, braids, yarns, fabrics, non-woven structures or the like; or (c) biodegradable inorganic (ceramic) file-ments, fibres, membrane fibres or the like or structures constructed thereof:
A particularly preferred embodiment of the invention is such an implant or an device which is structurally self-reinforced. A self--reinforced biodegradable structure is defined in the invention US Patent No. 4 743 257, Tormala, et al. In a self-reinforced struc-ture, a biodegradable polymer matrix is reinforced with biodegradable reinforcement elements (units) having the same proportional elemental composition as the matrix. The reinforcement elements are typically ori~emta.~ed moleculesv or parts thereof or the like obtained by orientation or fibrils, microfibrils, fibres, filaments or the like structures constructed thereof.
Reinforcement elements inside the microstructure of a self-reinforced polymer material are produced e.g. by orientating the molecular structure of a material either in melt state or in solid state in such condi-tions the structure-reinforcing orientation remains at least partially permanently in material either as a result of the rapid cooling and/or solid state of the melt and/or as a result of the prevention of molecular movements (relaxation) of the melt. The self-reinforcement based on draw orientation is described in the invention CVO 88/05312, Tormala et al., as follows:
A partially crystalline, non-oriented piece of polymer typically consists of crystal units i.e. spherulites and amorphous areas thereinside and/or therebetween.
The orientation and fibrillation of a polymer system possessing a spherulitic crystalline structure is a process that has been extensively studied in connection with the production of thermoplastic fibres. For example, the invention US Patent 3 161 709 discloses a three-step drawing process for.transforming a melt-worked polypropene filament into a fibre having a high tensile strength.
The mechanism of orientation and fibrillation is basically as follows (C. L. Choy et al. Polym. Eng.
Sci. 23, 1983, p. 910). As a partially crystalline polymer is being drawn, the molecule chains of crystal lamellae quickly begin to parallel themselves (orien-tate) in the drawing direction. Simultaneously the spherulites extend in length and finally break.
Crystal blocks detach from lamellae and join together as queues by means of tight tie-molecules which are formed through the partial release of polymer chains from crystal lamellae. The alternating amorphous and s ~~1. t~~, ~~, crystalline zones, together with tight tie-molecules, form long, thin (appr. 100 ~ wide) microfibrils which are paralleled in the drawing direction. Since the intrafibrillar tie-molecules form in the phase boun-daries between crystal blocks, they will be mainly located on the external surface of microfibrils.
Those tie-molecules, which link various lamellae in an isotropic material prior to drawing, serve in a fibrillated material to link various microfibrils together i.e. become interfibrillar tie-molecules which are located in boundary layers between'adjacent microfibrils.
Fig. 1 illustrates schematically the transformation of an array of lamellae into a fibrillar structure (a fibril consisting of a bunch of microfibrils) due to the action of water and fig. 2 shows some of the molecular structure inside and between miarofibrils.
Fig. 3 illustrates schematically some of the structure of a fibrillated polymer. The figure shows several fibrils (one being dyed grey for the sake of clarity) which consist of a plurality of micro.fibrils having a length, of several microns.
Orientation is initiated right at the start of drawing and also a fibrillated structure is formed at rather low drawing ratios x (wherein ~ - length of piece after drawing/length of piece prior to drawing). For example, HD-polyethene is clearly fibrillated at a value 8 and polyacetal (POM) at a value 3.
As the drawing of a fibrillated structure is continued further (this stage of the process is often referred to as ultra-orientation), the structure is further deformed with microfibrils sliding relative to each other to further increase the proportional volume of straightened interfibrillar tie-molecules. If drawing is effected at a sufficiently high temperature, the oriented tie-molecules crystallize and build axial crystalline bridges which link together crystalline blocks.
The excellent strength and modulus of elasticity properties of a fibrillated structure are based on the vigorous orientation of polymer molecules and polymer segments in the direction of drawing (in the direction of the longitudinal axis of microfibrils) characteris tic of the structure.
The fibrillation of macroscopic polymeric blanks, such as rods or tubes, is prior known in the cases of biostable polyacetal and polyethene (see e.g. K.
Nakagawa and T. iConaka, Polymer 27, 19$6, p. 1553 and references included therein). 'What has not been prior known, however, is the orientation and fibril lation of at least partially helical and/or spiral or similarly shaped members or pieces manufactured from biodegradable polymers.
The at least partial orientation and/or fibrillation of a biodegradable helical and/or spiral or similar piece can be effected e.g. by rapidly chilling a flowing state (e.g. in an injection mould) polymer w melt into a solid state in a manner that the orienta-tion of molecules existing in the flowing melt in flowing direction is not allowed to discharge through molecular movements either entirely or partially inta a state of random orientation.
A more vigorous orientation and fibrillation and thus also improved mechanica l qualities are generally provided for a polymer piece by mechanically working the material (orientation), generally drawing or hydrostatic extrusion or die-drawing in such a physical condition (usually in solid state), wherein it is possible for the material to undergo dramatic struc-tural deformations in its crystalline structures and amorphous areas occurring at molecular level for creating orientation and fibrillation. As a result of fibrillation, e.g. a resorbable polymer material produced by injection moulding or extrusion and initially possessing mainly a spherolitic crystalline structure transforms into a fibrillated structure which.
is vigorously oriented in the direction of drawing and comprises e.g, elongated crystalline microfibrils as well as tie-molecules linking them as well as oriented amorphous areas. In a partially fibrillated structure, the amorphous areas between microfibrils make up a more substantial portion. of the material than in an ultra-oriented material which, in the most preferred case, only includes amorphousness as crystal defects. As a result of orientation, fibrillation and ultra-orien tation the values of strength and modulus of elasticity of a material are multiplied compared to a non-fibril lated structure.
Orientation and the resulting fibrillation can be used for treating biodegradable polymers, copalymers and polymer compositions so as to farm self-reinforced composites in which nearly the entire material stock is oriented in a desired fashion and the portion of amorphous matrix is small, these being the reasons why such materials have extremely high quality strength properties in orientation direction: bending strength e.g. up to 400-1500 MPa and modulus of elasticity 20-50 GPa and thus the orientation and fibrillation can be used to provide helixes or spirals or the like devices with multiple strength values compared to those of normal melt-processed biodegradable materials, which are typically in the order of 30-80 MPa.
The same way as in the fibrillated structure of polymer fibres, also in the structure of fibrillated devices there can be found e.g. the following structural units which are schematically shown in fig. 4: crystalline blocks, the stock therebetween comprising an amorphous material (e.g. loose polymer chains, chain ends and molecular folds), tie-molecules which link the crystal-line blocks together (the number and tightness of these increases as drawing ratio a increases) as well as possible crystalline bridges between crystal-line blocks. Bridges can form during the drawing as tie-molecules orientate and group themselves as bridges (C. L. Choy et al. J. Polym. Sci., Polym. Phys. Ed., 19, 1981, p. 335).
The oriented fibrillated structure shown in figs. 1-4 is already developed by using so-called "natural"
drawing ratios 3-8. As drawing is then continued as ultra-orientation, the portion of crystalline bridges can increase to be quite considerable whereby, in the extreme case, the bridges and crystal blocks provide a continuous crystalline structure. However, the effects of tie-molecules and bridges are often similar and, thus, the exact distinction thereof from each other is not always possible.
Orientation and fibrillation can be experimentally characterized by the application of several different methods. Orientation function fc, which can be determined by X-ray diffraction measurements, charac-terizes orientation of the molecule chains of a crystalline phase. Generally, fc already reaches a maximum value of 1 by natural drawing ratios (a < 6).
For polymer materials having a spherolitic structure fc » 1.
Double-refraction ( ~;,) measured with a polarization microscope is also a quantity which represents the orientation of molecule chains. It generally increases at natural drawing ratios ( a < 6) vigorously and lz thereafter in ultra-orientation more slowly, which indicates that the molecule chains of a crystalline phase orientate vigorously in the drawing direction at natural drawing ratios and orientation of the molecules of an amorphous phase continues further at higher drawing ratios (C.L. Choy et al. Polym Eng. Sci., 23, 1983, p. 910).
The formation of a fibrillous structure can also be demonstrated visually by studying the fibrillated material by means of optical and/or electronic micros-copy (see e.g. T. Konaka et al. Polymer, 26, 1985, p.
462). Even the individual fibrils consisting of microfibrils can be clearly distinguished in scanning electron microscope images of a fibrillated structure.
An oriented and/or fibrillated and/or ultra-oriented piece (blank) is then rotated at least once around a centre of rotation into a helical configuration to form 20, "an device" of the invention by shaping it at least partially by means of an external force or pressure and/or external heat and/or by means of heat induceable in the piece (e.g. by radiowave radiation). In practice, the rotation of winding of the device is effected in a manner that an elongated blank is wound around a suitable, if necessary heated mould (e.g. a mould of cylindrical shape). Such a mould is typically round in cross-sectionso as to produce helical shapes having a circular cross-section. The cross-sectianal shape of a mould can also be elliptical, oval, angular etc, to produce helical shapes having various cross-sections. Orientation, fibrillation or ultra-orien-tation can also be effected in a continuous action and/or simultaneously with winding in a manner that an elongated blank is being drawn arid the drawn section is simultaneously wound around a cylindrical mould.
At least partially oriented and/or fibrillated and particularly yltra-oriented biodegradable devices are an example of an oriented, self-reinforced biodegrad-able (US Patent 4 743 257, T~irmala et al.) composite material, wherein the oriented reinforcement elements (such as fibrils, microfibrils, crystal blocks, tie-molecules or crystallized bridges) are formed and/or grouped during a mechanical working and a phase binding those elements consists e.g. of the following struc-tural elements: amorphous phase, interfaces between crystal blocks as well as interfaces between bridges and microfibrils, a typical feature of which is also a vigorous orientation in drawing direction.
Another method for using biodegradable reinforcement elements in devices of the invention is the reinforce-ment thereof with fibres manufactured from polymer, copolymer or a polymer composition, with film fibres, filaments or structures constructed threof, such as braids, threads, ribbons, non-woven structures, fabrics, knittings or the li:ke, by combining ready-made fibres with a suitable polydmer matrix. Such fibres can be manufactured E~.g. from biodegradable polymers set forth in table :l. The fibres can also be biodegradable ceramic fibres, such as calcium phosphate fibres (see e.g. S. Vainionpaa et al., Progr. Polym. Sci. , Progr. Polym. Sci., 14 (1989) 679-716.
Various plastic technological methods can be applied to manufacture devices of the invention reinforced with biodegradable organic and/or inorganic fibres or with structures constructed threof, said manufacturing being carried out by binding the reinforcement structures at least partially to each other with biodegradable polymer, copolymer or a polymer composition (matrix) in such conditions which serve to produce a sufficient-ly equal quality composite from the matrix and rein-forcement elements, said matrix being usually in solution or melt state. Methods for combining rein-forcement fibres or the like and a matrix as well as for processing them into semi-finished products and/or devices include e.g. injection moulding, extrusion, pultrusion, winding, compression moulding etc.
The at least partially spirally shaped, at least partially biodegradable device of the invention can be used in a versatile manner for supporting, expand-ing, joining or separating organs, tissues or parts threof. An device of the invention offers a plurality of benefits over the prior art implants and devices or devices. When using an device of the invention, the amount of foreign matter remains smaller than with traditional implant tubes. Devices of the invention are more flexible and resilient than the rigid prior art tubes and, on the other hand, devices of the invention are stronger under compression and retain their shape better than fibre-constructed tubular devices, whereby devices of the invention are capable of being used for retaining open or even expanding the medullary cavity of tubular tissues.
Devices of the invention can be manufactured from biodegradable polymers, copolymers and polymer compo-sitions. Table 1 shows a number of prior known biodegradable palymers, which or mixtures of which can be used as raw materials for devices of the invention both as a matrix (or binder polymers) and/or reinfor cement elements.
~'~~.~~
Table 1. Biodegradable polymers 1. Polyglycolide (PGA) Copolymers of alycolide 10 2. Glycolide/lactide copolymers (PGA/PLA) 3. Glycolide/trimethylene carbonate copolymers (PGA/TMC) Polylactides (PLA) Stereoisomers and copolymers of PLA
4. Poly-L-lactide (PLLA) 5. Poly-D-lactide (PDLA) 6. Poly-DL-lactide (PDLLA) 7. L-lactide/DL-lactide copolymers L-lactide/D-lactide copolymers Copolymers of PLA
8. Lactide/tetramethylene glycolide copolymers 9. Lactide/trimethylene carbonate copolymers 10. Lactide/6-valerolactone copolymers , 11. Lactide/E-caprolactone copolymers 12. Polydepsipeptides (glycine-DL-lactide copolymer) 13. PLA/ethylene oxide copolymers 14. Asymmetrically 3,6-substituted poly-1,4-dioxane-2,5-diones 15. Poly=J3-hydroxybutyrate (PHBA) 16. PHBA/J3-hydroxyvalerate copolymers (PHBA/PHVA) , 17. Poly-J3-hydroxypropionate (PHPA) 18. Poly-(i-dioxanone (PDS) 19. Poly-8-valerolactone 20. Poly-E-caprolactone 21. Methylmethacrylate-N-vinylpyrrolidone copolymers 22. Polyesteramides 23. Polyesters of oxalic acid 24. Polydihydropyranes 25. Polyalkyl-2-cyanoaarylates 26. Polyuretanes (PU) 27. Polyvinyl alcohol (PVA) 28. Polypeptides 29. Poly-j3-malefic acid (PMLA) 30. Poly-~3-alkanoic acids 31. Polyethylene oxide (PEO) 32. Chitin polymers Reference: S. Vainionpaa, P. Rokkanen and P. Tormala, Progr. Polym. Sci., in printing It is obvious that other biodegradable polymers than those set forth in table 1 can also be used as raw materials for implants, devices or parts thereof. For example, the biodegradable (absorbable) polymers described in the following publications can be used for the above purposes: US Patent No. 4 700 704 (Jamiolkows and Shalaby), US Patent No. 4 655 497 (Bezwada, Shalaby and Newman), US Patent No. 4 649 921 (Koelmel, Jamiol-kows and Bezwada), US Patent No. 4 559 945 (Koelmel and Shalaby), US Patent No. 4 532 928 (Rezada, Shalaby and Jamiolkows), US Patent No. 4 605 730 (Shalaby and Jamiolkows), US Patent No. 4 441 496 (Shalaby and Koelmel), US Patent No. 4 435 590 (Shalaby and Jamiol-kows), US Patent No. 4 559 945 (Koelmel and Shalaby).
It is also natural that devices of the invention may contain various additives and adjuvants for facilita-ting the processability of the material (e. g. stabili-zers, antioxidants or plasticizers) or for modifying the properties thereof (e. g. plastzcizers or powdered ceramic materials or biostable fibres, such as carbon fibres) or for facilitating the manipulation thereof (e. g. colourants).
According to one preferred embodiment, devices of the invention contain some bioactive agent or agents, such as antibiotics, chemotherapeutic agents, wound-healing agents, growth hormone, contraceptive agent, anticoa-gulant (such as heparin) etc. Such bioactive devices or devices are particularly preferred in clinical application since, in addition to mechanical effect, they have biochemical, medical and the like effects in various tissues.
Devices of the invention can also be advantageously combined with other types of biodegradable implants and devices. For example, by inserting a helical device as shown in figs. 7-10 into a tube woven or knitted from biodegradable and/or biostable thread there is obtained a firm and resilient tube which has a variety of applications in surgery for replacing or supporting tissues and/or for keeping open the cavities within or between tissues.
A device of the invention can also be fitted with long biodegradable rods which extend parallel to the longitudinal axis of e.g. a helical-shaped device.
Thus, if necessary, the device can be braced to form a tubular structure.
The device can also be fitted with various other accessories, such as flat perforated plates at the ends of a device for securing the ends of a device firmly to the surrounding tissues by means of surgical stitches.
Devices of the invention can have various geometrical configurations. Fig. 5 illustrates a flat or planar (in imaginary plane l) spiral 2 that can be used as a resilient separating material between tissues. The helixes of spiral 2 can also be connected with each other by means of biodegradable radial wires, rods 3 or the like as shown in fig. 6, the spiral having a high strength in the direction of plane 1 but being resilient in the direction perpendicular to that plane .
A device of the invention can also vary in its dimen-sions in various sections threof. For example, figs.
7a-l0a and 7b-lOb illustrate thematically a few such devices. These can be used for providing external and/or internal support for organs or their parts of various shapes (such as liver, spleen, kidneys, intestines etc.).
A device shown in fig. 7a is wound into a conical body. The conical body can have a side face outline which is either straight or arched or a combination thereof according to intended application. Devices shown in figs. 8a and 9a include two conical bodies joined to each other either at the base of conical bodies (fig. 8a) or at the apex threof (fig. 9a).
Fig. 10a illustrates a device having its outer face wound into a cylindrical configuration.
Figs. 7b, 8b, 9b and 10b illustrate device configurat-ions matching those of figs. 7a, 8a, 9a and 10a and fitted with rods 3 connecting the turns of a helical body.
Furthermore, fig. lOc shows an embodiment in which the device is comprised of two nested device elements V01 and V02 wound into a helical configuration preferably in opposite directions. Each has cylindrical helical configuration. Fig. lOd shows an embodiment of a device, wherein a number of device olements wound into a helical configuration have been twined together.
The device elements are adapted to run alternately over and under each other to form a tubular structure.
Figs. lla-111 illustrate same types of cross-section for a blank. A blank for manufacturing devices of the invention can have a cross-section which is e.g.
circular (lla), elliptical (llb, llc), flat (lld, lle), angular (llf, llg, 11h), asteroid (lli) etc.
By varying the cross-section of a blank it is possible to effect e.g: on the mechanical properties of a device, the growth of tissues on the surface of a blank and the growth of tissues through the device.
The thickness of a blank can also vary in different sections of a blank or it can be provided with holes R (llj) or similar structures, such as recesses L
(llk) or slots (111) for facilitating the fastening or securing threof to tissues.
According to one preferred embodiment, a device of the invention is manufactured by winding or rolling a flat blank having a cross-section shown in fig. 12 into a tube as shown in fig. 13. Since the longitudinal edges of a blank (see figs. l2a and 13a) are provided with folded or otherwise designed gripping means T which engage each other, during the winding there will be formed a flexibletube that can be used in the treat-ment of a . g . a windpipe or the like flexible tissue channels as a temporary prothesis.
According to one preferred embodiment, devices of the invention can be used join together tissues, organs or parts thereof, such as muscular tissue or the like soft tissues. Such embodiment is illustrated in fig. 18.
Fig. 18a shows a cross-section of a tissue K1 and a tissue K2 which should be joined with each other. The joining can be effected by using a sharp-pointed spiral S which is driven the same way as a corkscrew through the tissues {fig. 18b). By locking the top portion of a spiral in position after the turning (e.g. by stitching the spiral firmly to surrounding tissues by means of surgical stitches disssolving through the holes made in the spiral blank) said spiral serves to secure tissues K1 and K2 to each other preventing the separation or sliding 'thereof relative to each other.
The invention and its applicability is described in more detail by means of the following examples.
EXAMPLE 1.
Some polymers set forth in table 1 were used to prepare helical devices of the invention, such as that shown in fig. 10 (blank thickness 1 mm, outer diameter of helix 6 mm, inner diameter 4 mm, pitch angle 15 degrees and length of device 20-50 mm), by subjecting the polymeric melt to injection moulding to produce blanks having a diameter (~) of 1.5 - 2.0 mm by drawing (orientation and self-reinforcement) them at a tempe-rature of Tm > T > Tg (wherein Tg is polymer glazing temperature and Tm is polymer (possibly) melting temperature) to the QS reading of 1 mm and by winding them in hot state around a metal pipe (diameter 4 mm) as well as by cooling the device and by removing the finished device from the surface of the metal pipe.
Reference materials were made by using similar polymers to prepare tubular pieces (tube length 10 mm, outer diameter 6 mm and inner diameter 4 mm) by injection moulding polydmer melt into a Gaoled tubular mould.
The compression strength of the devices and that of the corresponding tubes were compared to each other by squeezing a device (fig. 14b) or a tube (fig. 14a) placed between two steel plates with an external force in the direction orthogonal to its longitudinal axis. The bending of a device in lateral direction was prevented by prepressing the device into a compact bundle between two vertical plates (fig. 14b).
The compression load strengths of a tube (fig. 14a) and a device (fig. 14b) made of the same polymer and having equal weights were compared to each other. This was followed by the determination of the relative compres-sion load strength (SP) of the device - a force required to fracture the device/a force required to fracture the tube. Devices and tubes were manufactured by using the following biodegradable polydmers, copolymers and polymer compositions: polyglycolide (Mw 60 000), glycolide/lactide copolymer (Mw 40 000), glycolide/trimethylenecarbonate copolymer (Mw 60000), PLLA (Mw 260 000), PDLLA (Mw 100 000), lactide/8-valerolactone copolymer (Mw 60 000), lactide/E-capro-lactone copolymer (Mw 60 000), PHBA (Mw 700 000), PHPA (Mw 50 000) and PDS (Mw 40 000). Resulting values for SP were ranging between 1.8 - 12.
EXAMPLE 2.
Devices of the invention such as that shown in fig. 10 were prepared by using a biodegradable polymer matrix as well as biodegradable reinforcing fibres included threin as reinforcements by compression moulding a bundle of parallel fibres and fine particulate polymer powder (particle size 1-10 Vim) mixed therein (thermo plastic polymers) in a rod-shaped mould (length 8 cm, 1.5 mm) above the melting point (partially crystal line polymers) or glazing point (amorphous polymers) of the matrix polymer: The amount of reinforcing fibres was 40-60 ~ by volume. The rod blanks were wound in a heated condition helically around a hot cylindrica l mould (outer diameter of helix 8 mm) and the mould was cooled. When using a reaction polymer (n-butylcyano acrylate) as a matrix, the bundle of reinforcing fibres was rapidly impregnated with cyanoacrylate and the uncured wetted bundle of threads was wound helically around a teflon-coated steel pipe followed by wetting and removing the device. A
corresponding device was made by using just cyano acrylate.
Impregnation technique was also applied when using a matrix containing segmented polyurethane (S. Gogolewski and A. Pennings, Makromol. Chem. Rapid Comm. 4, 1983, p. 213) which was dissolved in N,N°'-dimethylformamide-/tetrahydrofurane solution (weight ratio 3/2). Then, the bundle of fibres helically wound on the surface of a teflon-coated pipe was impregnated at 80 degrees with a polyurethane solution and the pipe was immersed in a mixture of ethanol/distilled water (1:1). This process was repeated several times for preparing the device. A corresponding device was made by using just polyurethane.
Devices corresponding to such reinforced devices were also manufactured from mere thermoplastic matrix polymers by the application of melt working technique.
Table 2 illustrates the matrix polymers and fibrous reinforcements for the devices prepared.
Table 2. Structural components for fibre-reinforced biodegradable devices.
Matrix polymer Fibre reinforcement PDS PGA
-"- PGA/TMC
-"- PGA/PLLA
-"- PLLA
_"_ PHBA
-"- PHBA/HVA
-"- Chitin fibre -"- PDS
PDLLA PGA
_"_ PGA/TMC
_ PGA/PLLA
_ PLLA
_"_ pHBA
-"- PHBA/HVA
_"_ PDS' -"- PALLA
PLLA PGA
-"- PGA/TMC
' _"- PLLA
PVA PGA
-" PGA/TMC
"_ PGA/PLLA
_"_ ~LLA
" pHBA
" pHBA/HVA
-"- pDS
-"- Chitin fibres PGA/TMC PGA
- PGA/TMC
PHBA PGA
-"- PGA/TMC
-"- pHBA
Poly-E-caprolactone PGA
-"- PGA/TMC
4 _ " -- PHBA
Methylmetacrylate- PGA
N-vinylpyrrolidone Polyurethane PGA
Collagen (catgut) PEO PGA
_ - PGA/TMC
"- PGA/PLA
"_ PLLA
n-Butylcyano- Collagen (catgut) acrylate PGA
~~~.~~'7~
The devices were secured by their ends to a tension apparatus and were drawn until broken in the direction of the longitudinal axis of the device (winding axis of the blank). This was followed by the determination of the relative tensile load-bearing strength (SV) of a reinforced device = a force required to fracture a reinforced device/a force required to fracture a corresponding non-reinforced device. The SV values were ranging between 1.5 - 8.
EXAMPLE 3.
Preparation of a self-reinforced polylactide device as shown in fig. 10 (hereinb~low "heli:x" (KR) (raw material poly-L-lactide/poly-DL-lactide copolymer (PLLA/PDLLA molar ratio 80/20), Mw = 60 000). Helix (KR) was manufactured from a thick, extrusion-made PLLA/PDLLA rod which was drawn to a drawing ratio of a = 7 at a temperature of 90 degrees for self-rein forcing the material. A thus prepared self-reinforced rod having a thickness of l mm was then wound to form "a helix" as described in example 1. The helix was cut into lengths of 12 mm for the following examina tion.
The gastric cavity of a dog was opened in general anaesthesia, the rotes roes were set aside and the bile duct (ST) was exposed by preparation (see fig. 15).
A roughly 6 mm long incision (AK1) was made threin.
As shown in fig. 15a, a distance of 5 mm of this incision was provided with non-resorbable stitches (KO) (which pucker up the duct and narrow it permanent-ly together with a cica~rical tissue formed on incision (AK1). This was followed by closing the gastric cavity, stitching the skin and, after waking up from anaesthesia, the dog was allowed to move freely in its cage. After one month the dog was re-anesthetized, the gastric cavity was incised and the blocked bile ' duct was prepared to re-expose it. The duct was opened with a longitudinal incision (AK2) at the region of cicatricial pucker, a helix having an inner diameter of 2 mm and an outer diameter of 3 mm was inserted in the bile duct in a manner that both of its ends were located in healthy bile duct and its central portion within the incised pucker region.
The bile duct was closed with a stitch (0), whereby its walls extended around the spiral. The situation is schematically illustrated in the cross-sectional figure 15c. After the operation, the bile duct was normal in volume. The gastric cavity and skin were closed the same way as in the first operation. The dog was put away after 14 months by~which time the helix had nearly disappeared and the bile duct had a normal extent and volume and the pucker was no longer macroscopically observable.
EXAMPLE 4.
The femoral vein (RL in fig. l6a) of a dog was cut in general anaesthesia in the right hind leg. The base portion of the more distal vein wasthreaded into the interior of a biodegradable, reinforced device ("hel-ix") having an inner diameter of 8 mm and an outer diameter of 9 mm and a length of 2 am, said device being like the one shown in fig. 10 (reinforcing fibres: Ca/P-fibres; matrix polymer PLLA, Mw - 100 000; fibre/polymer weight ratio - 30/70 (w/w) and vein (LO) was stitched with end-to-end technique by using a resorbable 6-0 yarn to make a tight seam with no bleeding. After the operation, due to the flabbi-ness of the walls, the vein tended to collapse within the region of the stitched seam and this leads to a poorer circulation in the vein resulting easily in the development of a coagulation or a clot formed by blood particles within the region of the seam and thus the vein will be blocked. The situation is illustrated in the schematic view of fig. 16a from the side of stitched seam and in fig. 16b from above a stitched seam. Therefore, a biodegradable helix (KR) was pulled over the seam portion with the stitched seam remaining at the half-way point of helix (KR) . The wall of a vein was attached at the stitched seam over its entire circumference to the helix by means of non-resorbable support stitches (TO) (fig. l6c). ,This way the vein was tensioned to its normal extent with the help of a support provided by the device. After the seam had healed, especially after the inner surface of a blood vessel or endothelium had healed, there is no longer a risk of developing a clot and the helix can resorb away with no harm done. After 6 months the dog was put away and the femoral vein had healed without a pucker or a clot.
EXAMPLE 5.
The test animals were male rabbits weighing 3'kg. The animals were anesthetized for the operation with im.
ketamin and iv. pentobarbital preparations: A poly-lactide blank (~ 1 mm) was used to prepare a helix having an outer diameter of 8'mm and a length of 15 mm and an extension formed by athin tubular neck section, 10 mm, followed by two helical coils (fig:
17).
The anesthetized test animals were subjected to a surgical incision of the urinary bladder through abdominal covers. Thxough the opened bladder the prothesis was threaded into position with the narrow neck section remaining within the region of closure muscle and the helical coil ends on the side of the urinary bladder.
The prothesis was fitted in 15 test animals which were under observation for 3 months . The study verified that an implant of the invention can be used for preventing a lower urethra obstruction caused by the enlargement of forebland.
EXAMPLE 6.
The test animals were male rabbits weighing appr. 3 kg. The animals were anesthetized for the operation with im. ketamin and iv. pentobarbital preparations.
The implants employed were PLLA helixes as described in example 1 (cross-section of blank circular, thick-ness of blank l mm, outer diameter of helix 6 mm and length 15 mm).
On the anesthetized test animals was performed scission of the blind urethra to the extent suf f icient for a prothesis . The prothesis was placed on the distal side of closure muscle. In connection with the operation an antibiotic as a single dose: ampicillin 100 mg/kg.
The prothesis was fitted in l5 animals which were put away with iv overdose of anesthetic 2 weeks, 3 months, 6 months, 1 year and 2 years after the implantation.
The urethra was dissected and tissue samples were taken for histological and electron microscopic analysis.
Histological studies indicatedd that PLLA had caused only slight foreign matter reaction in tissues. 2 years after the implantation the helix hadnearly completely biodegraded and the urethra was almost normal in its dimensions.
2 s ~r~.~~'''J~
EXAMPLE 7.
Cloggings in the ureters leading from kidney to bladder will become more common as a result of the increased observation surgery of upper urethras. The ureter has a good regeneration ability when subjected lon-gitudinal incision but its healing requires an internal support. Transverse incision or short deficiency always leads to the development of a clogging.
The purpose of this example was to examine the app licability of a helix made of a biodegradable material both to the healing of a longitudinal dissection of the urethra and to the healing of a transverse de ficiency.
The test animals were female rabbits weighing appr. 3 kg. The animals were anesthetized. Incision of the abdominal cavity was performed on the flank without opening, however, the actual abdominal cavity.
a) the urethra having a diameter of ca. 9 mm was dissected lengthwise over'a distance of ca. 2, cm followed by threading a self-reinforced PGA-helix (blank thickness l mm) inside the urethra, said helix having an outer diameter of 4 mm and a length of 20 mm. The region of dissection was co~rered with fat.
b) a length of ca. 1 cm was cut off the urethra, the remaining ends were dissected over a distance of 0.5 cm and the above-described prothesis was threaded in, so that the remaining defect zone of the tissue was l cm. The defect zone was covered with sur-rounding fat. After l month, 3 months and Z year from the operation a tracer imaging of the kidneys was performed for observing the healing of urethra.
The operated urethras had healed to almost normal condition over the period of 1 year (on the basi s of tracer imaging).
It is also natural that devices of the invention may contain various additives and adjuvants for facilita-ting the processability of the material (e. g. stabili-zers, antioxidants or plasticizers) or for modifying the properties thereof (e. g. plastzcizers or powdered ceramic materials or biostable fibres, such as carbon fibres) or for facilitating the manipulation thereof (e. g. colourants).
According to one preferred embodiment, devices of the invention contain some bioactive agent or agents, such as antibiotics, chemotherapeutic agents, wound-healing agents, growth hormone, contraceptive agent, anticoa-gulant (such as heparin) etc. Such bioactive devices or devices are particularly preferred in clinical application since, in addition to mechanical effect, they have biochemical, medical and the like effects in various tissues.
Devices of the invention can also be advantageously combined with other types of biodegradable implants and devices. For example, by inserting a helical device as shown in figs. 7-10 into a tube woven or knitted from biodegradable and/or biostable thread there is obtained a firm and resilient tube which has a variety of applications in surgery for replacing or supporting tissues and/or for keeping open the cavities within or between tissues.
A device of the invention can also be fitted with long biodegradable rods which extend parallel to the longitudinal axis of e.g. a helical-shaped device.
Thus, if necessary, the device can be braced to form a tubular structure.
The device can also be fitted with various other accessories, such as flat perforated plates at the ends of a device for securing the ends of a device firmly to the surrounding tissues by means of surgical stitches.
Devices of the invention can have various geometrical configurations. Fig. 5 illustrates a flat or planar (in imaginary plane l) spiral 2 that can be used as a resilient separating material between tissues. The helixes of spiral 2 can also be connected with each other by means of biodegradable radial wires, rods 3 or the like as shown in fig. 6, the spiral having a high strength in the direction of plane 1 but being resilient in the direction perpendicular to that plane .
A device of the invention can also vary in its dimen-sions in various sections threof. For example, figs.
7a-l0a and 7b-lOb illustrate thematically a few such devices. These can be used for providing external and/or internal support for organs or their parts of various shapes (such as liver, spleen, kidneys, intestines etc.).
A device shown in fig. 7a is wound into a conical body. The conical body can have a side face outline which is either straight or arched or a combination thereof according to intended application. Devices shown in figs. 8a and 9a include two conical bodies joined to each other either at the base of conical bodies (fig. 8a) or at the apex threof (fig. 9a).
Fig. 10a illustrates a device having its outer face wound into a cylindrical configuration.
Figs. 7b, 8b, 9b and 10b illustrate device configurat-ions matching those of figs. 7a, 8a, 9a and 10a and fitted with rods 3 connecting the turns of a helical body.
Furthermore, fig. lOc shows an embodiment in which the device is comprised of two nested device elements V01 and V02 wound into a helical configuration preferably in opposite directions. Each has cylindrical helical configuration. Fig. lOd shows an embodiment of a device, wherein a number of device olements wound into a helical configuration have been twined together.
The device elements are adapted to run alternately over and under each other to form a tubular structure.
Figs. lla-111 illustrate same types of cross-section for a blank. A blank for manufacturing devices of the invention can have a cross-section which is e.g.
circular (lla), elliptical (llb, llc), flat (lld, lle), angular (llf, llg, 11h), asteroid (lli) etc.
By varying the cross-section of a blank it is possible to effect e.g: on the mechanical properties of a device, the growth of tissues on the surface of a blank and the growth of tissues through the device.
The thickness of a blank can also vary in different sections of a blank or it can be provided with holes R (llj) or similar structures, such as recesses L
(llk) or slots (111) for facilitating the fastening or securing threof to tissues.
According to one preferred embodiment, a device of the invention is manufactured by winding or rolling a flat blank having a cross-section shown in fig. 12 into a tube as shown in fig. 13. Since the longitudinal edges of a blank (see figs. l2a and 13a) are provided with folded or otherwise designed gripping means T which engage each other, during the winding there will be formed a flexibletube that can be used in the treat-ment of a . g . a windpipe or the like flexible tissue channels as a temporary prothesis.
According to one preferred embodiment, devices of the invention can be used join together tissues, organs or parts thereof, such as muscular tissue or the like soft tissues. Such embodiment is illustrated in fig. 18.
Fig. 18a shows a cross-section of a tissue K1 and a tissue K2 which should be joined with each other. The joining can be effected by using a sharp-pointed spiral S which is driven the same way as a corkscrew through the tissues {fig. 18b). By locking the top portion of a spiral in position after the turning (e.g. by stitching the spiral firmly to surrounding tissues by means of surgical stitches disssolving through the holes made in the spiral blank) said spiral serves to secure tissues K1 and K2 to each other preventing the separation or sliding 'thereof relative to each other.
The invention and its applicability is described in more detail by means of the following examples.
EXAMPLE 1.
Some polymers set forth in table 1 were used to prepare helical devices of the invention, such as that shown in fig. 10 (blank thickness 1 mm, outer diameter of helix 6 mm, inner diameter 4 mm, pitch angle 15 degrees and length of device 20-50 mm), by subjecting the polymeric melt to injection moulding to produce blanks having a diameter (~) of 1.5 - 2.0 mm by drawing (orientation and self-reinforcement) them at a tempe-rature of Tm > T > Tg (wherein Tg is polymer glazing temperature and Tm is polymer (possibly) melting temperature) to the QS reading of 1 mm and by winding them in hot state around a metal pipe (diameter 4 mm) as well as by cooling the device and by removing the finished device from the surface of the metal pipe.
Reference materials were made by using similar polymers to prepare tubular pieces (tube length 10 mm, outer diameter 6 mm and inner diameter 4 mm) by injection moulding polydmer melt into a Gaoled tubular mould.
The compression strength of the devices and that of the corresponding tubes were compared to each other by squeezing a device (fig. 14b) or a tube (fig. 14a) placed between two steel plates with an external force in the direction orthogonal to its longitudinal axis. The bending of a device in lateral direction was prevented by prepressing the device into a compact bundle between two vertical plates (fig. 14b).
The compression load strengths of a tube (fig. 14a) and a device (fig. 14b) made of the same polymer and having equal weights were compared to each other. This was followed by the determination of the relative compres-sion load strength (SP) of the device - a force required to fracture the device/a force required to fracture the tube. Devices and tubes were manufactured by using the following biodegradable polydmers, copolymers and polymer compositions: polyglycolide (Mw 60 000), glycolide/lactide copolymer (Mw 40 000), glycolide/trimethylenecarbonate copolymer (Mw 60000), PLLA (Mw 260 000), PDLLA (Mw 100 000), lactide/8-valerolactone copolymer (Mw 60 000), lactide/E-capro-lactone copolymer (Mw 60 000), PHBA (Mw 700 000), PHPA (Mw 50 000) and PDS (Mw 40 000). Resulting values for SP were ranging between 1.8 - 12.
EXAMPLE 2.
Devices of the invention such as that shown in fig. 10 were prepared by using a biodegradable polymer matrix as well as biodegradable reinforcing fibres included threin as reinforcements by compression moulding a bundle of parallel fibres and fine particulate polymer powder (particle size 1-10 Vim) mixed therein (thermo plastic polymers) in a rod-shaped mould (length 8 cm, 1.5 mm) above the melting point (partially crystal line polymers) or glazing point (amorphous polymers) of the matrix polymer: The amount of reinforcing fibres was 40-60 ~ by volume. The rod blanks were wound in a heated condition helically around a hot cylindrica l mould (outer diameter of helix 8 mm) and the mould was cooled. When using a reaction polymer (n-butylcyano acrylate) as a matrix, the bundle of reinforcing fibres was rapidly impregnated with cyanoacrylate and the uncured wetted bundle of threads was wound helically around a teflon-coated steel pipe followed by wetting and removing the device. A
corresponding device was made by using just cyano acrylate.
Impregnation technique was also applied when using a matrix containing segmented polyurethane (S. Gogolewski and A. Pennings, Makromol. Chem. Rapid Comm. 4, 1983, p. 213) which was dissolved in N,N°'-dimethylformamide-/tetrahydrofurane solution (weight ratio 3/2). Then, the bundle of fibres helically wound on the surface of a teflon-coated pipe was impregnated at 80 degrees with a polyurethane solution and the pipe was immersed in a mixture of ethanol/distilled water (1:1). This process was repeated several times for preparing the device. A corresponding device was made by using just polyurethane.
Devices corresponding to such reinforced devices were also manufactured from mere thermoplastic matrix polymers by the application of melt working technique.
Table 2 illustrates the matrix polymers and fibrous reinforcements for the devices prepared.
Table 2. Structural components for fibre-reinforced biodegradable devices.
Matrix polymer Fibre reinforcement PDS PGA
-"- PGA/TMC
-"- PGA/PLLA
-"- PLLA
_"_ PHBA
-"- PHBA/HVA
-"- Chitin fibre -"- PDS
PDLLA PGA
_"_ PGA/TMC
_ PGA/PLLA
_ PLLA
_"_ pHBA
-"- PHBA/HVA
_"_ PDS' -"- PALLA
PLLA PGA
-"- PGA/TMC
' _"- PLLA
PVA PGA
-" PGA/TMC
"_ PGA/PLLA
_"_ ~LLA
" pHBA
" pHBA/HVA
-"- pDS
-"- Chitin fibres PGA/TMC PGA
- PGA/TMC
PHBA PGA
-"- PGA/TMC
-"- pHBA
Poly-E-caprolactone PGA
-"- PGA/TMC
4 _ " -- PHBA
Methylmetacrylate- PGA
N-vinylpyrrolidone Polyurethane PGA
Collagen (catgut) PEO PGA
_ - PGA/TMC
"- PGA/PLA
"_ PLLA
n-Butylcyano- Collagen (catgut) acrylate PGA
~~~.~~'7~
The devices were secured by their ends to a tension apparatus and were drawn until broken in the direction of the longitudinal axis of the device (winding axis of the blank). This was followed by the determination of the relative tensile load-bearing strength (SV) of a reinforced device = a force required to fracture a reinforced device/a force required to fracture a corresponding non-reinforced device. The SV values were ranging between 1.5 - 8.
EXAMPLE 3.
Preparation of a self-reinforced polylactide device as shown in fig. 10 (hereinb~low "heli:x" (KR) (raw material poly-L-lactide/poly-DL-lactide copolymer (PLLA/PDLLA molar ratio 80/20), Mw = 60 000). Helix (KR) was manufactured from a thick, extrusion-made PLLA/PDLLA rod which was drawn to a drawing ratio of a = 7 at a temperature of 90 degrees for self-rein forcing the material. A thus prepared self-reinforced rod having a thickness of l mm was then wound to form "a helix" as described in example 1. The helix was cut into lengths of 12 mm for the following examina tion.
The gastric cavity of a dog was opened in general anaesthesia, the rotes roes were set aside and the bile duct (ST) was exposed by preparation (see fig. 15).
A roughly 6 mm long incision (AK1) was made threin.
As shown in fig. 15a, a distance of 5 mm of this incision was provided with non-resorbable stitches (KO) (which pucker up the duct and narrow it permanent-ly together with a cica~rical tissue formed on incision (AK1). This was followed by closing the gastric cavity, stitching the skin and, after waking up from anaesthesia, the dog was allowed to move freely in its cage. After one month the dog was re-anesthetized, the gastric cavity was incised and the blocked bile ' duct was prepared to re-expose it. The duct was opened with a longitudinal incision (AK2) at the region of cicatricial pucker, a helix having an inner diameter of 2 mm and an outer diameter of 3 mm was inserted in the bile duct in a manner that both of its ends were located in healthy bile duct and its central portion within the incised pucker region.
The bile duct was closed with a stitch (0), whereby its walls extended around the spiral. The situation is schematically illustrated in the cross-sectional figure 15c. After the operation, the bile duct was normal in volume. The gastric cavity and skin were closed the same way as in the first operation. The dog was put away after 14 months by~which time the helix had nearly disappeared and the bile duct had a normal extent and volume and the pucker was no longer macroscopically observable.
EXAMPLE 4.
The femoral vein (RL in fig. l6a) of a dog was cut in general anaesthesia in the right hind leg. The base portion of the more distal vein wasthreaded into the interior of a biodegradable, reinforced device ("hel-ix") having an inner diameter of 8 mm and an outer diameter of 9 mm and a length of 2 am, said device being like the one shown in fig. 10 (reinforcing fibres: Ca/P-fibres; matrix polymer PLLA, Mw - 100 000; fibre/polymer weight ratio - 30/70 (w/w) and vein (LO) was stitched with end-to-end technique by using a resorbable 6-0 yarn to make a tight seam with no bleeding. After the operation, due to the flabbi-ness of the walls, the vein tended to collapse within the region of the stitched seam and this leads to a poorer circulation in the vein resulting easily in the development of a coagulation or a clot formed by blood particles within the region of the seam and thus the vein will be blocked. The situation is illustrated in the schematic view of fig. 16a from the side of stitched seam and in fig. 16b from above a stitched seam. Therefore, a biodegradable helix (KR) was pulled over the seam portion with the stitched seam remaining at the half-way point of helix (KR) . The wall of a vein was attached at the stitched seam over its entire circumference to the helix by means of non-resorbable support stitches (TO) (fig. l6c). ,This way the vein was tensioned to its normal extent with the help of a support provided by the device. After the seam had healed, especially after the inner surface of a blood vessel or endothelium had healed, there is no longer a risk of developing a clot and the helix can resorb away with no harm done. After 6 months the dog was put away and the femoral vein had healed without a pucker or a clot.
EXAMPLE 5.
The test animals were male rabbits weighing 3'kg. The animals were anesthetized for the operation with im.
ketamin and iv. pentobarbital preparations: A poly-lactide blank (~ 1 mm) was used to prepare a helix having an outer diameter of 8'mm and a length of 15 mm and an extension formed by athin tubular neck section, 10 mm, followed by two helical coils (fig:
17).
The anesthetized test animals were subjected to a surgical incision of the urinary bladder through abdominal covers. Thxough the opened bladder the prothesis was threaded into position with the narrow neck section remaining within the region of closure muscle and the helical coil ends on the side of the urinary bladder.
The prothesis was fitted in 15 test animals which were under observation for 3 months . The study verified that an implant of the invention can be used for preventing a lower urethra obstruction caused by the enlargement of forebland.
EXAMPLE 6.
The test animals were male rabbits weighing appr. 3 kg. The animals were anesthetized for the operation with im. ketamin and iv. pentobarbital preparations.
The implants employed were PLLA helixes as described in example 1 (cross-section of blank circular, thick-ness of blank l mm, outer diameter of helix 6 mm and length 15 mm).
On the anesthetized test animals was performed scission of the blind urethra to the extent suf f icient for a prothesis . The prothesis was placed on the distal side of closure muscle. In connection with the operation an antibiotic as a single dose: ampicillin 100 mg/kg.
The prothesis was fitted in l5 animals which were put away with iv overdose of anesthetic 2 weeks, 3 months, 6 months, 1 year and 2 years after the implantation.
The urethra was dissected and tissue samples were taken for histological and electron microscopic analysis.
Histological studies indicatedd that PLLA had caused only slight foreign matter reaction in tissues. 2 years after the implantation the helix hadnearly completely biodegraded and the urethra was almost normal in its dimensions.
2 s ~r~.~~'''J~
EXAMPLE 7.
Cloggings in the ureters leading from kidney to bladder will become more common as a result of the increased observation surgery of upper urethras. The ureter has a good regeneration ability when subjected lon-gitudinal incision but its healing requires an internal support. Transverse incision or short deficiency always leads to the development of a clogging.
The purpose of this example was to examine the app licability of a helix made of a biodegradable material both to the healing of a longitudinal dissection of the urethra and to the healing of a transverse de ficiency.
The test animals were female rabbits weighing appr. 3 kg. The animals were anesthetized. Incision of the abdominal cavity was performed on the flank without opening, however, the actual abdominal cavity.
a) the urethra having a diameter of ca. 9 mm was dissected lengthwise over'a distance of ca. 2, cm followed by threading a self-reinforced PGA-helix (blank thickness l mm) inside the urethra, said helix having an outer diameter of 4 mm and a length of 20 mm. The region of dissection was co~rered with fat.
b) a length of ca. 1 cm was cut off the urethra, the remaining ends were dissected over a distance of 0.5 cm and the above-described prothesis was threaded in, so that the remaining defect zone of the tissue was l cm. The defect zone was covered with sur-rounding fat. After l month, 3 months and Z year from the operation a tracer imaging of the kidneys was performed for observing the healing of urethra.
The operated urethras had healed to almost normal condition over the period of 1 year (on the basi s of tracer imaging).
Claims (24)
1. A surgical implant, device, or a part thereof made of a biodegradable material, which has been composed of a biodegradable matrix with biodegradable reinforcement elements therein, the said implant being at least partially wound at least once around a winding centre into a helical configuration, characterized in that the implant or device for separating tubular tissues and/or keeping open a tissue cavity in operated and/or damaged tissues is formed of one single rod.
2. An implant, device or a part thereof as set forth in claim 1, characterized in that the rod is at least partially wound into a spiral configuration.
3. An implant, device or a part thereof as set forth in claim 2, characterized in that the rod is at least partially wound into a screw-threaded configuration.
4. An implant, device or a part thereof as set forth in claim 2, characterized in that at least some of the spirals are connected with each other by means of biodegradable radial wires or rods.
5. An implant, device or a part thereof as set forth in claim 3, characterized in that at least some of the screw threads are connected with each other by means of biodegradable radial wires or rods.
6. An implant, device or a part thereof as set forth in claim 3, characterized in that the helically shaped screw-threaded configuration of the rod is cylindrical.
7. An implant, device or a part thereof as set forth in claim 3, characterized in that the helically shaped screw-threaded configuration of the rod is conical.
8. An implant, device or a part thereof as set forth in claim 1, characterized in that the reinforcement elements consist of oriented structures formed at least partially by polymer molecules.
9. An implant, device or a part thereof as set forth in claim 1 or 8, characterized in that the reinforcement elements comprise at least partially micro-fibrils, fibrils or structures formed thereby.
10. An implant, device or a part thereof as set forth in any one of claims 1, 8 and 9, characterized in that the reinforcement elements are at least partially fibres, film fibres, wires, braids, ribbons, staples, non-woven constructions, fabrics, knittings or corresponding structures constructed of fibres.
11. An implant, device or a part thereof as set forth in any one of claims 1 and 8 to 10, characterized in that the reinforcement elements are at least partially biodegradable ceramic fibres.
12. An implant, device or a part thereof as set forth in any one of claims 1 and 8 to 11, characterized in that the reinforcement elements further comprise biostable fibres.
13. An implant, device or a part thereof as set forth in any one of claims 1 and 8 to 12, characterized in that the reinforcement elements are at least partially biodegradable ceramic fibres.
14. An implant, device or a part thereof as set forth in any one of claims 1 and 8 to 13, characterized in that it is structurally at least partially self-reinforced.
15. An implant, device or a part thereof as set forth in any one of claims 1 and 8 to 14, characterized by comprising at least two, at least partially helical device sections joined to each other, said device sections being at least partially nested within each other.
16. An implant, device or a part thereof as set forth in claim 15, characterized by comprising at least two device sections which are twined together to form a substantially tubular structure.
17. A method for manufacturing an implant or a device as set forth in any one of claims 1 to 16, characterized in that an elongated blank formed by a biodegradable polymer matrix and biodegradable reinforcement elements is wound at least partially at least once around a winding centre into a helical configuration.
18. A method as set forth in claim 17, characterized by (a) orienting and/or fibrillating and/or ultra-orienting an elongated piece made of an at least partially biodegradable polymer, copolymer or polymer composition by means of mechanical draw and/or rapid cooling of a flowing melt, followed by (b) winding it at least partially into a helical configuration by working it by the application of an external force or pressure and/or heat.
19. A method as set forth in claims 17 or 18, characterized in that a plurality of blanks are wound simultaneously around a common winding centre.
20. A method as set forth in claim 19, characterized in that during the winding said blanks are driven over and under each other for producing a tubular braid.
21. The application of an implant, device or a part thereof as set forth in any one of claims 1 to 16, as an anti-pucker or anti-blocking and/or expanding device for a channel, a duct, a tube or a blood vessel and/or as an anastomosis device.
22. The application of an implant, device or a part thereof as set forth in any one of claims 1 to 16, as devices for joining together tissues, organs or parts thereof.
23. The implant, device or part thereof as set forth in claim 12, wherein the biostable fibres are polymeric fibres and/or ceramic fibres.
24. The implant, device or part thereof as set forth in claim 15, wherein the at least two, at least partially helical device sections are joined to each other in a manner that the helixes turn in opposite directions.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002010274A CA2010274C (en) | 1988-11-10 | 1990-02-16 | Biodegradable surgical implants and devices |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI885164A FI85223C (en) | 1988-11-10 | 1988-11-10 | BIODEGRADERANDE SURGICAL IMPLANT OCH MEDEL. |
| CA002010274A CA2010274C (en) | 1988-11-10 | 1990-02-16 | Biodegradable surgical implants and devices |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2010274A1 CA2010274A1 (en) | 1991-08-16 |
| CA2010274C true CA2010274C (en) | 2001-04-03 |
Family
ID=25673959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002010274A Expired - Fee Related CA2010274C (en) | 1988-11-10 | 1990-02-16 | Biodegradable surgical implants and devices |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2010274C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111925227B (en) * | 2020-01-19 | 2022-04-08 | 湖南碳康生物科技有限公司 | Carbon fiber composite material artificial trachea stent and preparation method thereof |
-
1990
- 1990-02-16 CA CA002010274A patent/CA2010274C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2010274A1 (en) | 1991-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU636311B2 (en) | Biodegradable surgical implants and devices | |
| US6171338B1 (en) | Biodegradable surgical implants and devices | |
| CA1311689C (en) | Surgical materials and devices | |
| US6709452B1 (en) | Biodegradable surgical implants | |
| US6524345B1 (en) | Surgical implant | |
| FI88111B (en) | SJAELVFOERSTAERKANDE SURGICAL MATERIAL OCH MEDEL | |
| JP3779327B2 (en) | Degradable material under tissue conditions and method for producing the same | |
| EP3019209B1 (en) | Soft suture anchors | |
| EP0861097B1 (en) | Biodegradable implant manufactured of polymer-based material and a method for manufacturing the same | |
| US7582108B2 (en) | Tubular implant | |
| JP2909116B2 (en) | Reinforced polymer film for biofunctional materials | |
| EP2344079A2 (en) | Fracture fixation systems | |
| US20080255561A1 (en) | Medical device | |
| CA2010274C (en) | Biodegradable surgical implants and devices |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |